Trial Profile
Phase I Additional Study of Tolerance and Pharmacokinetics of Anlotinib in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2019
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 15 Sep 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
- 15 Sep 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
- 24 Apr 2017 Planned End Date changed from 1 Oct 2016 to 1 Apr 2017.